Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Clinical Research

The combination of histological prostate atrophy and inflammation is associated with lower risk of prostate cancer in biopsy specimens

Prostate Cancer and Prostatic Diseases volume 20, pages 413–417 (2017)Cite this article

Subjects

Abstract

Background:

To evaluate whether the presence of both prostate atrophy (PA) and chronic prostate inflammation (CPI) in the same biopsy and in the same biopsy core are associated with prostate cancer (PCa) risk and grade in repeat biopsies.

Methods:

Retrospective analyses of 6132 men who were 50–75 years old undergoing 2-year repeat prostate biopsy after a negative baseline biopsy for PCa in the REduction by DUtasteride of prostate Cancer Events (REDUCE) study. PA, CPI and PCa were determined by central pathology. The association of baseline PA and CPI with 2-year repeat biopsy cancer status and grade was evaluated with χ2 test and logistic regression controlling clinicopathological features.

Results:

PA, CPI and both were detected in 583 (9.5%), 1063 (17.4%) and 3675 (59.9%) baseline biopsies, respectively. Compared with biopsies with neither PA nor CPI, the presence of PA (odds ratio (OR)=0.73, 95% confidence interval (CI)=0.57–0.93), CPI (OR=0.72, 95% CI=0.58–0.88) and both (OR=0.54, 95% CI=0.45–0.64) were associated with lower PCa risk in the 2-year repeat prostate biopsy. Results were similar in multivariable analysis. Among subjects with both PA and CPI, those with both findings in the same core had even lower PCa risk compared with PA and CPI in different cores (univariable OR=0.68, 95% CI=0.51–0.91; multivariable OR=0.73, 95% CI=0.54–0.99). Combination of PA and CPI was associated with lower risk of high-grade PCa.

Conclusions:

The presence of both PA and CPI in baseline biopsies, especially in the same core, was associated with lower PCa risk and grade. The presence and topographical distribution of PA and CPI may be used in PCa risk stratification.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Moore CK, Karikehalli S, Nazeer T, Fisher HA, Kaufman RP Jr, Mian BM . Prognostic significance of high grade prostatic intraepithelial neoplasia and atypical small acinar proliferation in the contemporary era. J Urol 2005; 173: 70–72.

    Article  Google Scholar 

  2. Moreira DM, Nickel JC, Gerber L, Muller RL, Andriole GL, Castro-Santamaria R et al. Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study. Cancer 2014; 120: 190–196.

    Article  CAS  Google Scholar 

  3. Moreira DM, Nickel JC, Andriole GL, Castro-Santamaria R, Freedland SJ . Chronic baseline prostate inflammation is associated with lower tumor volume in men with prostate cancer on repeat biopsy: results from the REDUCE study. Prostate 2015; 75: 1492–1498.

    Article  Google Scholar 

  4. Moreira DM, Nickel JC, Andriole GL, Castro-Santamaria R, Freedland SJ . Greater extent of prostate inflammation in negative biopsies is associated with lower risk of prostate cancer on repeat biopsy: results from the REDUCE study. Prostate Cancer Prostatic Dis 2016; 19: 180–184.

    Article  CAS  Google Scholar 

  5. Moreira DM, Bostwick DG, Andriole GL, Peterson BL, Cohen HJ, Castro-Santamaria R et al. Baseline prostate atrophy is associated with reduced risk of prostate cancer in men undergoing repeat prostate biopsy. J Urol 2015; 194: 1241–1246.

    Article  Google Scholar 

  6. Servian P, Celma A, Planas J, Placer J, de Torres IM, Olivan M et al. Clinical significance of proliferative inflammatory atrophy finding in prostatic biopsies. Prostate 2015; 75: 1669–1675.

    Article  Google Scholar 

  7. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192–1202.

    Article  CAS  Google Scholar 

  8. Abrahams NA, Bostwick DG, Ormsby AH, Qian J, Brainard JA . Distinguishing atrophy and high-grade prostatic intraepithelial neoplasia from prostatic adenocarcinoma with and without previous adjuvant hormone therapy with the aid of cytokeratin 5/6. Am J Clin Pathol 2003; 120: 368–376.

    Article  Google Scholar 

  9. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS . Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial. J Urol 2007; 178: 896–900.

    Article  Google Scholar 

  10. Wu C, Moreira DM, Gerber L, Rittmaster RS, Andriole GL, Freedland SJ . Diabetes and prostate cancer risk in the REDUCE trial. Prostate Cancer Prostatic Dis 2011; 14: 326–331.

    Article  CAS  Google Scholar 

  11. Berney DM, Algaba F, Camparo P, Comperat E, Griffiths D, Kristiansen G et al. Variation in reporting of cancer extent and benign histology in prostate biopsies among European pathologists. Virchows Arch 2014; 464: 583–587.

    Article  CAS  Google Scholar 

  12. Schatteman PH, Hoekx L, Wyndaele JJ, Jeuris W, Van Marck E . Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Eur Urol 2000; 37: 404–412.

    Article  CAS  Google Scholar 

  13. Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M et al. Prevalence of inflammation and benign prostatic hyperplasia on autopsy in Asian and Caucasian men. Eur Urol 2014; 66: 619–622.

    Article  Google Scholar 

  14. Delongchamps NB, de la Roza G, Chandan V, Jones R, Sunheimer R, Threatte G et al. Evaluation of prostatitis in autopsied prostates—is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol 2008; 179: 1736–1740.

    Article  Google Scholar 

  15. Postma R, Schroder FH, van der Kwast TH . Atrophy in prostate needle biopsy cores and its relationship to prostate cancer incidence in screened men. Urology 2005; 65: 745–749.

    Article  CAS  Google Scholar 

  16. Porcaro AB, Novella G, Molinari A, Terrin A, Minja A, De Marco V et al. Prostate volume index and chronic inflammation of the prostate type IV with respect to the risk of prostate cancer. Urol Int 2015; 94: 270–285.

    Article  CAS  Google Scholar 

  17. Yun BH, Hwang EC, Yu HS, Chung H, Kim SO, Jung SI et al. Is histological prostate inflammation in an initial prostate biopsy a predictor of prostate cancer on repeat biopsy? Int Urol Nephrol 2015; 47: 1251–1257.

    Article  CAS  Google Scholar 

  18. Brasil AA, Favaro WJ, Cagnon VH, Ferreira U, Billis A . Atrophy in specimens of radical prostatectomy: is there topographic relation to high-grade prostatic intraepithelial neoplasia or cancer? Int Urol Nephrol 2011; 43: 397–403.

    Article  Google Scholar 

  19. Billis A, Magna LA . Inflammatory atrophy of the prostate. Prevalence and significance. Arch Pathol Lab Med 2003; 127: 840–844.

    PubMed  Google Scholar 

  20. Iczkowski KA, Torkko KC, Wilson RS, Lucia MS, Bostwick DG . Prostatic atrophy: its spatial proximity to carcinoma and intraepithelial neoplasia based on annotation of digital slides. Hum Pathol 2014; 45: 54–58.

    Article  Google Scholar 

  21. De Marzo AM, Platz EA, Epstein JI, Ali T, Billis A, Chan TY et al. A working group classification of focal prostate atrophy lesions. Am J Surg Pathol 2006; 30: 1281–1291.

    Article  Google Scholar 

  22. Wang W, Bergh A, Damber JE . Morphological transition of proliferative inflammatory atrophy to high-grade intraepithelial neoplasia and cancer in human prostate. Prostate 2009; 69: 1378–1386.

    Article  Google Scholar 

  23. Van Leenders GJ, Gage WR, Hicks JL, van Balken B, Aalders TW, Schalken JA et al. Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am J Pathol 2003; 162: 1529–1537.

    Article  CAS  Google Scholar 

  24. Celma A, Servián P, Planas J, Placer J, Quilez MT, Arbós MA et al. Clinical significance of proliferative inflammatory atrophy in prostate biopsy. Acta Urol Esp 2014; 38: 122–126.

    Article  CAS  Google Scholar 

  25. Servian P, Celma A, Planas J, Placer J, de Torres IM, Morote J . Clinical significance of proliferative inflammatory atrophy in negative prostatic biopsies. Prostate 2016; 76: 1501–1506.

    Article  Google Scholar 

  26. Al-Azab R, Toi A, Lockwood G, Kulkarni GS, Fleshner N . Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL. Urology 2007; 69: 103–107.

    Article  Google Scholar 

  27. Freitas DM, Andriole GL, Castro-Santamaria R, Freedland SJ, Moreira DM . Extent of baseline prostate atrophy is associated with lower incidence of low- and high-grade prostate cancer on repeat biopsy. Urology 2016; 103: 161–166.

    Article  Google Scholar 

Download references

Acknowledgements

Data were provided by GSK. No funding was provided for this study.

Author information

Authors and Affiliations

  1. Department of Urology, University of Illinois at Chicago, Chicago, IL, USA

    D M Moreira

  2. University of Southern California, Los Angeles, CA, USA

    D M de O Freitas

  3. Nossa Senhora da Conceição Hospital, Porto Alegre, Brazil

    D M de O Freitas

  4. Department of Urology, Queen's University, Kingston, ON, Canada

    J C Nickel

  5. Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, St Louis, MO, USA

    G L Andriole

  6. GlaxoSmithKline, Global R&D, King of Prussia, Pennsylvania, PA, USA

    R Castro-Santamaria

  7. Division of Urology, Department of Surgery, Cedars Sinai Medical Center, Los Angeles, CA, USA

    S J Freedland

Authors
  1. D M Moreira
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D M de O Freitas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J C Nickel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G L Andriole
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Castro-Santamaria
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S J Freedland
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D M Moreira.

Ethics declarations

Competing interests

I certify that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/ affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received or pending) are the following: DdOF, JCN and DMM have no disclosures; GLA Jr: consulting and advisory board (GlaxoSmithKline, PLC), speaker fees (GlaxoSmithKline, PLC), research support (GlaxoSmithKline, PLC); RC-S: employee (GlaxoSmithKline, PLC); SF: research support (GlaxoSmithKline, PLC)

.

Additional information

Supplementary Information accompanies the paper on the Prostate Cancer and Prostatic Diseases website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moreira, D., de O Freitas, D., Nickel, J. et al. The combination of histological prostate atrophy and inflammation is associated with lower risk of prostate cancer in biopsy specimens. Prostate Cancer Prostatic Dis 20, 413–417 (2017). https://doi.org/10.1038/pcan.2017.30

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2017.30

This article is cited by

Search

Advanced search

Quick links